QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.107.041459v1 73/5/1474    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsushima, S. Articles by Sugiyama, Y. Search for Related Content PubMed PubMed Citation Articles by Matsushima, S. Articles by Sugiyama, Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB TERFENADINE

Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine

Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan. (S.M., K.M., H.H., Y.D., H.K., Y.S.); Division of Experimental Therapy, the Netherlands Cancer Institute, Amsterdam, the Netherlands (A.H.S.); and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee (J.D.S.)

Fexofenadine (FEX) is mainly eliminated from the liver into bile in unchanged form. We demonstrated previously that organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 are involved in the hepatic uptake of FEX. However, little is known about the mechanisms controlling the hepatic efflux of FEX from the liver to bile and blood. In the present study, the involvement of hepatic efflux transporters in the pharmacokinetics of FEX was investigated in both in vitro and in vivo studies. Vectorial transport of FEX was observed in OATP1B3/human bile salt export pump (hBSEP) double transfectants but not in OATP1B3/human breast cancer resistance protein double transfectants, which indicates the possible contribution of hBSEP to the biliary excretion of FEX in humans. In multidrug resistance-associated protein 2 (Mrp2)^-/- mice, the biliary excretion clearance based on the plasma concentration and the liver-to-plasma concentration ratio significantly decreased, whereas the biliary excretion clearance based on the liver concentration decreased only with 20%, suggesting the minimum contribution of Mrp2 to its biliary excretion. ATP-dependent transport of FEX was observed in hMRP3-enriched membrane vesicles but not hMRP4. In Mrp3^-/- mice, the biliary excretion clearance based on both the plasma and liver concentration and the liver-to-plasma concentration ratio increased, suggesting the significant contribution of Mrp3 to its sinusoidal efflux and the up-regulation of its biliary excretion in Mrp3^-/- mice. On the other hand, pharmacokinetics of FEX remained unchanged in Mrp4^-/- mice. This information provides a novel insight into the transporters important for FEX disposition.

Received for publication September 3, 2007.

Accepted for publication February 1, 2008.

Address correspondence to: Dr. Yuichi Sugiyama, Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp

This article has been cited by other articles:

				A. Dahan, H. Sabit, and G. L. Amidon Multiple Efflux Pumps Are Involved in the Transepithelial Transport of Colchicine: Combined Effect of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 Leads to Decreased Intestinal Absorption Throughout the Entire Small Intestine Drug Metab. Dispos., October 1, 2009; 37(10): 2028 - 2036. [Abstract] [Full Text] [PDF]

				T. D. Nolin, R. F. Frye, P. Le, H. Sadr, J. Naud, F. A. Leblond, V. Pichette, and J. Himmelfarb ESRD Impairs Nonrenal Clearance of Fexofenadine but not Midazolam J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2269 - 2276. [Abstract] [Full Text] [PDF]

				A. Dahan and G. L. Amidon Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting Am J Physiol Gastrointest Liver Physiol, August 1, 2009; 297(2): G371 - G377. [Abstract] [Full Text] [PDF]

				T. Watanabe, K. Maeda, T. Kondo, H. Nakayama, S. Horita, H. Kusuhara, and Y. Sugiyama Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments Drug Metab. Dispos., July 1, 2009; 37(7): 1471 - 1479. [Abstract] [Full Text] [PDF]

				S. Matsushima, K. Maeda, K. Inoue, K.-y. Ohta, H. Yuasa, T. Kondo, H. Nakayama, S. Horita, H. Kusuhara, and Y. Sugiyama The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine Drug Metab. Dispos., March 1, 2009; 37(3): 555 - 559. [Abstract] [Full Text] [PDF]

				Y. Kitamura, M. Hirouchi, H. Kusuhara, J. D. Schuetz, and Y. Sugiyama Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 465 - 473. [Abstract] [Full Text] [PDF]

				E. Y. H. Yeung, T. Sueyoshi, M. Negishi, and T. K. H. Chang Identification of Ginkgo biloba as a Novel Activator of Pregnane X Receptor Drug Metab. Dispos., November 1, 2008; 36(11): 2270 - 2276. [Abstract] [Full Text] [PDF]